All In Biotech

Drug Trial Radar · NCT05638126

Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects

A Phase I Single and Multiple Ascending Dose and Food Effect Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-1780 Tablets in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Oct 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

96

Actual

Start

Feb 2, 2023

Primary completion

Dec 2023

Study completion Dec 2023

Sponsor

Sponsor type
Industry
First posted
Dec 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled phase I clinical study. The primary objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose HRS-1780 in healthy subjects, and to evaluate the food effect on PK of HRS-1780.

Conditions

  • Chronic Kidney Disease

Interventions

  • HRS-1780 table or placeboDrug

    HRS-1780 table or placebo single dose

  • HRS-1780 table or placeboDrug

    HRS-1780 table or placebo single dose with food effect

  • HRS-1780 table or placeboDrug

    HRS-1780 table or placebo multiple dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the incidence and severity of adverse events in healthy subjects after single and multiple doses of HRS-1780 tabletsTime frame: About a month from the first medication to the evaluation.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.